Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded
- Contract number
- SPE2DB25FPRS9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $148,649
Award facts
- Contract value 100% obligated
- $148,649.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $148,649.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on September 29, 2025, with an ultimate completion date of September 30, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent contract performance across diverse medication categories, from specialty biologics to oncology treatments and routine pharmaceuticals. The company's status as a woman-owned small business has enabled it to compete effectively in federal procurement while maintaining a robust portfolio of delivery orders with the DLA. The current award for Trikafta, a cystic fibrosis treatment, reflects the company's continued role in delivering specialized pharmaceutical products to military and federal healthcare systems across the nation.
Quick answers
Who was awarded contract SPE2DB25FPRS9?
SPE2DB25FPRS9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 29, 2025.
How much is contract SPE2DB25FPRS9 worth?
The government has obligated $148,649 on SPE2DB25FPRS9.
Is contract SPE2DB25FPRS9 an order under another contract?
Yes. SPE2DB25FPRS9 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRS9 competed?
The extent of competition for SPE2DB25FPRS9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award